Proteomic and biomarker studies and neurological complications of pediatric sickle cell disease

Proteomics - Clinical Applications

Volumn 8, Issue 11-12, 2014, Pages 813-827

  Lance, Eboni I ^a,b   Casella, James F ^b   Everett, Allen D ^b   Barron Casella, Emily ^b  

^a KENNEDY KRIEGER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biological markers; Neurodevelopment; Sickle cell; Stroke

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 1BETA; L SELECTIN; PLATELET DERIVED GROWTH FACTOR AA; THROMBOSPONDIN 1; PLATELET DERIVED GROWTH FACTOR; PROTEOME;

BRAIN INFARCTION; BRAIN INJURY; BRAIN ISCHEMIA; CHILD; CHILDHOOD DISEASE; DISEASE ASSOCIATION; DOPPLER ECHOGRAPHY; ERYTHROCYTE DERIVED MICROPARTICLE; HUMAN; INTELLECTUAL IMPAIRMENT; INTELLIGENCE QUOTIENT; MAJOR CLINICAL STUDY; MEMBRANE MICROPARTICLE; NEUROLOGICAL COMPLICATION; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN URINE LEVEL; PROTEOMICS; REVIEW; RISK FACTOR; SICKLE CELL ANEMIA; SYSTEMATIC REVIEW; COMPLICATION; METABOLISM; NEUROLOGIC DISEASE; PROCEDURES;

ANEMIA, SICKLE CELL; BIOMARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHILD; HUMANS; NERVOUS SYSTEM DISEASES; PLATELET-DERIVED GROWTH FACTOR; PROTEOME; PROTEOMICS;

EID: 84912526116     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201400069     Document Type: Review

References (75)

1. King, A. A., DeBaun, M. R., White, D. A., Need for cognitive rehabilitation for children with sickle cell disease and strokes. Expert. Rev. Neurother. 2008, 8, 291-296.
2. Ohene-Frempong, K., Weiner, S. J., Sleeper, L. A., Miller, S. T. et al., Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998, 91, 288-294.
3. DeBaun, M. R., Armstrong, F. D., McKinstry, R. C., Ware, R. E. et al., Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood 2012, 119, 4587-4596.
4. Bernaudin, F., Verlhac, S., Arnaud, C., Kamdem, A. et al., Impact of early transcranial doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood 2011, 117, 1130-1140.
5. Berkelhammer, L. D., Williamson, A. L., Sanford, S. D., Dirksen, C. L. et al., Neurocognitive sequelae of pediatric sickle cell disease: a review of the literature. Child Neuropsychol. 2007, 13, 120-131.
6. Webb, J., Kwiatkowski, J. L., Stroke in patients with sickle cell disease. Expert. Rev. Hematol. 2013, 6, 301-316.
7. Jordan, L. C., Casella, J. F., DeBaun, M. R., Prospects for primary stroke prevention in children with sickle cell anaemia. Br. J. Haematol. 2012, 157, 14-25.
8. DeBaun, M. R., Sarnaik, S. A., Rodeghier, M. J., Minniti, C. P. et al., Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood 2012, 119, 3684-3690.
9. Kirkham, F. J., Hewes, D. K., Prengler, M., Wade, A. et al., Nocturnal hypoxaemia and central-nervous-system events in sickle-cell disease. Lancet 2001, 357, 1656-1659.
10. Wang, W. C., Gallagher, D. M., Pegelow, C. H., Wright, E. C. et al., Multicenter comparison of magnetic resonance imaging and transcranial doppler ultrasonography in the evaluation of the central nervous system in children with sickle cell disease. J. Pediatr. Hematol. Oncol. 2000, 22, 335-339.
11. Adams, R., McKie, V., Nichols, F., Carl, E. et al., The use of transcranial ultrasonography to predict stroke in sickle cell disease. N. Engl. J. Med. 1992, 326, 605-610.
12. Adams, R. J., McKie, V. C., Hsu, L., Files, B. et al., Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. N. Engl. J. Med. 1998, 339, 5-11.
13. Rees, D. C., Gibson, J. S., Biomarkers in sickle cell disease. Br. J. Haematol. 2012, 156, 433-445.
14. Wick, T. M., Eckman, J. R., Molecular basis of sickle cell-endothelial cell interactions. Curr. Opin. Hematol. 1996, 3, 118-124.
15. Brittain, J. E., Parise, L. V., The alpha4beta1 integrin in sickle cell disease. Transfus. Clin. Biol. 2008, 15, 19-22.
16. Goodman, S. R., Daescu, O., Kakhniashvili, D. G., Zivanic, M., The proteomics and interactomics of human erythrocytes. Exp. Biol. Med. 2013, 238, 509-518.
17. Yuditskaya, S., Suffredini, A. F., Kato, G. J., The proteome of sickle cell disease: insights from exploratory proteomic profiling. Expert. Rev. Proteomics. 2010, 7, 833-848.
18. Savage, W. J., Everett, A. D., Biomarkers in pediatrics: children as biomarker orphans. Proteomics Clin. Appl. 2010, 4, 915-921.
19. Biomarkers Definitions Working Group, Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69, 89-95.
20. Niebanck, A. E., Pollock, A. N., Smith-Whitley, K., Raffini, L. J. et al., Headache in children with sickle cell disease: prevalence and associated factors. J. Pediatr. 2007, 151, 67-72.
21. Prengler, M., Pavlakis, S. G., Boyd, S., Connelly, A. et al., Sickle cell disease: ischemia and seizures. Ann. Neurol. 2005, 58, 290-302.
22. Mourad, H., Fadel, W., El Batch, M., Rowisha, M., Heamostatic and genetic predisposing factors for stroke in children with sickle cell anemia. Egypt J. Immunol. 2008, 15, 25-37.
23. Tantawy, A. A., Adly, A. A., Ismail, E. A., Habeeb, N. M., Farouk, A., Circulating platelet and erythrocyte microparticles in young children and adolescents with sickle cell disease: relation to cardiovascular complications. Platelets 2013, 24, 605-614.
24. Savage, W. J., Barron-Casella, E., Fu, Z., Dulloor, P. et al., Plasma glial fibrillary acidic protein levels in children with sickle cell disease. Am. J. Hematol. 2011, 86, 427-429.
25. Pegelow, C. H., Macklin, E. A., Moser, F. G., Wang, W. C. et al., Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood 2002, 99, 3014-3018.
26. Asare, K., Gee, B. E., Stiles, J. K., Wilson, N. O. et al., Plasma interleukin-1(beta) concentration is associated with stroke in sickle cell disease. Cytokine 2010, 49, 39-44.
27. Hyacinth, H. I., Gee, B. E., Adamkiewicz, T. V., Adams, R. J. et al., Plasma BDNF and PDGF-AA levels are associated with high TCD velocity and stroke in children with sickle cell anemia. Cytokine 2012, 60, 302-308.
28. Savage, W. J., Everett, A. D., Casella, J. F., Plasma glial fibrillary acidic protein levels in a child with sickle cell disease and stroke. Acta Haematol. 2011, 125, 103-106.
29. O'Driscoll, S., Height, S. E., Dick, M. C., Rees, D. C., Serum lactate dehydrogenase activity as a biomarker in children with sickle cell disease. Br. J. Haematol. 2008, 140, 206-209.
30. Faulcon, L. M., Fu, Z., Dulloor, P., Barron-Casella, E. et al., Thrombospondin-1 and L-selectin are associated with silent cerebral infarct in children with sickle cell anaemia. Br. J. Haematol. 2013, 162, 421-424.
31. Hyacinth, H. I., Adams, R. J., Voeks, J. H., Hibbert, J. M., Gee, B. E., Frequent red cell transfusions reduced vascular endothelial activation and thrombogenicity in children with sickle cell anemia and high stroke risk. Am. J. Hematol. 2014, 89, 47-51.
32. Montaner, J., Perea-Gainza, M., Delgado, P., Ribo, M. et al., Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 2008, 39, 2280-2287.
33. Jickling, G. C., Sharp, F. R., Blood biomarkers of ischemic stroke. Neurotherapeutics 2011, 8, 349-360.
34. Laborde, C. M., Mourino-Alvarez, L., Akerstrom, F., Padial, L. R. et al., Potential blood biomarkers for stroke. Expert. Rev. Proteomics 2012, 9, 437-449.
35. Barnes, C., Deveber, G., Prothrombotic abnormalities in childhood ischaemic stroke. Thromb. Res. 2006, 118, 67-74.
36. Eleftheriou, D., Ganesan, V., Hong, Y., Klein, N. J., Brogan, P. A., Endothelial injury in childhood stroke with cerebral arteriopathy: a cross-sectional study. Neurology 2012, 79, 2089-2096.
37. Adams, R. J., McKie, V. C., Brambilla, D., Carl, E. et al., Stroke prevention trial in sickle cell anemia. Control Clin. Trials 1998, 19, 110-129.
38. Casella, J. F., King, A. A., Barton, B., White, D. A. et al., Design of the silent cerebral infarct transfusion (SIT) trial. Pediatr. Hematol. Oncol. 2010, 27, 69-89.
39. Ennen, C. S., Huisman, T. A., Savage, W. J., Northington, F. J. et al., Glial fibrillary acidic protein as a biomarker for neonatal hypoxic-ischemic encephalopathy treated with whole-body cooling. Am. J. Obstet. Gynecol. 2011, 205, 251.e1-e7.
40. Papa, L., Silvestri, S., Brophy, G. M., Giordano, P. et al., GFAP out-performs S100B in detecting traumatic intracranial lesions on CT in trauma patients with mild traumatic brain injury and those with extracranial lesions. J. Neurotrauma. 2014, ahead of print, doi: 10.1089/neu.2013.3245.
41. Zhang, Z., Zoltewicz, J. S., Mondello, S., Newsom, K. J. et al., Human traumatic brain injury induces autoantibody response against glial fibrillary acidic protein and its breakdown products. PLoS One 2014, 9, e101712.
42. Quinn, C. T., McKinstry, R. C., Dowling, M. M., Ball, W. S. et al., Acute silent cerebral ischemic events in children with sickle cell anemia. JAMA Neurol. 2013, 70, 58-65.
43. Novelli, E. M., Kato, G. J., Ragni, M. V., Zhang, Y. et al., Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates. Am. J. Hematol. 2012, 87, 326-330.
44. Okpala, I., Daniel, Y., Haynes, R., Odoemene, D., Goldman, J., Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells. Eur. J. Haematol. 2002, 69, 135-144.
45. Sanchez, C. E., Schatz, J., Roberts, C. W., Cerebral blood flow velocity and language functioning in pediatric sickle cell disease. J. Int. Neuropsychol. Soc. 2010, 16, 326-334.
46. Armstrong, F. D., Elkin, T. D., Brown, R. C., Glass, P. et al., Developmental function in toddlers with sickle cell anemia. Pediatrics 2013, 131, e406-e414.
47. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Publishing, Arlington, VA 2013.
48. Hjalmarsson, C., Bjerke, M., Andersson, B., Blennow, K. et al., Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke. J. Cent. Nerv. Syst. Dis. 2014, 19, 51-58.
49. Martinez-Morillo, E., Garcia Hernandez, P., Begcevic, I., Kosanam, H. et al., Identification of novel biomarkers of brain damage in patients with hemorrhagic stroke by integrating bioinformatics and mass spectrometry-based proteomics. J. Proteome Res. 2014, 7, 969-981.
50. Husseini, N. E., Laskowitz, D. T., Clinical application of blood biomarkers in cerebrovascular disease. Expert. Rev. Neurother. 2010, 10, 189-203.
51. Ning, M. M., Lopez, M., Sarracino, D., Cao, J. et al., Pharmaco-proteomics opportunities for individualizing neurovascular treatment. Neurol. Res. 2013, 35, 448-456.
52. Saenger, A. K., Christenson, R. H., Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment. Clin. Chem. 2009, 56, 21-33.
53. Anand, N., Stead, L. G., Neuron-specific enolase as a marker for acute ischemic stroke: a systematic review. Cerebrovasc. Dis. 2005, 20, 213-219.
54. Akpinar, O., Geyik, S., Acikalin, A., Karakan, Y., Tiryaki, O., H-FABP in the early diagnosis of stroke. J. Neurol. 2009, 256, 1922-1923.
55. Zimmermann-Ivol, C. G., Burkhard, P. R., Le Floch-Rohr, J., Allard, L. et al., Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study. Mol. Cell Proteomics 2004, 3, 66-72.
56. Wunderlich, M. T., Hanhoff, T., Goertler, M. et al., Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke. J. Neurol. 2005, 252, 718-724.
57. Dambinova, S. A., Khounteev, G. A., Izykenova, G. A., Zavolokov, I. G. et al., Blood test detecting autoantibodies to N-methyl-d-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin. Chem. 2003, 49, 1752-1762.
58. Laterza, O. F., Modur, V. R., Crimmins, D. L. et al., Identification of novel brain biomarkers. Clin. Chem. 2006, 52, 1713-1721.
59. Stroick, M., Fatar, M., Ragoschke-Schumm, A., Fassbender, K. et al., Protein S-100B-a prognostic marker for cerebral damage. Curr. Med Chem. 2006, 13, 3053-3060.
60. Foerch, C., Singer, O. C., Neumann-Haefelin, T., Mesnil de Rochemont, R. et al., Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch. Neurol. 2005, 62, 1130-1134.
61. Jauch, E. C., Lindsell, C., Broderick, J., Fagan, S. C. et al., Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke 2006, 37, 2508-2513.
62. Foerch, C., Curdt, I., Yan, B., Dvorak, F. et al., Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J. Neurol. Neurosurg. Psychiatry 2006, 77, 181-184.
63. Dvorak, F., Haberer, I., Sitzer, M., Foerch, C., Characterisation of the diagnostic window of serum glial fibrillary acidic protein for the differentiation of intracerebral haemorrhage and ischaemic stroke. Cerebrovasc. Dis. 2009, 27, 37-41.
64. Herrmann, M., Vos, P., Wunderlich, M. T., de Bruijn, C. H., Lamers, K. J., Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 2000, 31, 2670-2677.
65. Strouse, J. J., Jordan, L. C., Lanzkron, S., Casella, J. F., The excess burden of stroke in hospitalized adults with sickle cell disease. Am. J. Hematol. 2009, 84, 548-552.
66. Shet, A. S., Aras, O., Gupta, K., Hass, M. J. et al., Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003, 102, 2678-2683.
67. Setty, B. N., Key, N. S., Rao, A. K., Gayen-Betal, S. et al., Tissue factor-positive monocytes in children with sickle cell disease: correlation with biomarkers of haemolysis. Br. J. Haematol. 2012, 157, 370-380.
68. McKinney, C. M., Kelher, M. R., Silliman, C. C., Changes in cell-derived plasma microparticles during the acute chest syndrome in children with sickle cell disease. Blood 2013, 122, abstract.
69. Murugappan, S., López, J. A., in: Marder, V. J., Aird, W. C., Bennett, J. S., Schulman, S., White, G. C., (Eds.), (Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 6th ed., Lippincott-Raven Publishers Philadelphia, PA 2012, pp. 475-491.
70. Setty, Y., Gayen-Betal, S., Krishnan, S., Meier, M. et al., Imbalance in arachidonic acid to docosahexaenoic acid ratios in the sickle red cell is associated with inflammation. Blood 2009, 114, abstract.
71. Shiu, Y. T., Udden, M. M., McIntire, L. V., Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells. Blood 2000, 95, 3232-3241.
72. Sultana, C., Shen, Y., Johnson, C., Kalra, V. K., Cobalt chloride-induced signaling in endothelium leading to the augmented adherence of sickle red blood cells and transendothelial migration of monocyte-like HL-60 cells is blocked by PAF-receptor antagonist. J. Cell Physiol. 1999, 179, 67-78.
73. Joneckis, C. C., Shock, D. D., Cunningham, M. L., Orringer, E. P., Parise, L. V., Glycoprotein IV-independent adhesion of sickle red blood cells to immobilized thrombospondin under flow conditions. Blood 1996, 87, 4862-4870.
74. Joneckis, C. C., Ackley, R. L., Orringer, E. P., Wayner, E. A., Parise, L. V., Integrin alpha 4 beta 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia. Blood 1993, 82, 3548-3555.
75. Sugihara, K., Sugihara, T., Mohandas, N., Hebbel, R. P., Thrombospondin mediates adherence of CD36 +sickle reticulocytes to endothelial cells. Blood 1992, 80, 2634-2642.